ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

09 أغسطس 2024 12:49:53 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

07 أغسطس 2024 09:01:10 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

06 أغسطس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

28 يونيو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

09 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 أبريل 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 أبريل 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

21 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

07 مارس 2024 16:05:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

06 مارس 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

26 فبراير 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

22 فبراير 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 فبراير 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 فبراير 2024 09:01:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 نوفمبر 2023 16:00:00 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

09 نوفمبر 2023 11:02:36 بحسب Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

06 أكتوبر 2023 09:03:00 بحسب Nasdaq GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

03 أكتوبر 2023 09:03:40 بحسب Nasdaq GlobeNewswire

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

19 سبتمبر 2023 22:49:48 بحسب Nasdaq GlobeNewswire

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

10 أغسطس 2023 16:00:00 بحسب Nasdaq GlobeNewswire